BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 38706713)

  • 1. Fibroblast Activation Protein Inhibitor Theranostics: Early Clinical Translation.
    Mori Y; Kratochwil C; Haberkorn U; Giesel FL
    PET Clin; 2023 Jul; 18(3):419-428. PubMed ID: 37030981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Characterization of Novel FAP-Targeted Theranostic Pairs: A Bench-to-Bedside Study.
    Huang W; Pang Y; Liu Q; Liang C; An S; Wu Q; Zhang Y; Huang G; Chen H; Liu J; Wei W
    Research (Wash D C); 2023; 6():0282. PubMed ID: 38706713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Fibroblast Activation Protein Inhibitor-Based Dimeric Radiotracers with Improved Tumor Retention and Antitumor Efficacy.
    Zhao L; Chen J; Pang Y; Fang J; Fu K; Meng L; Zhang X; Guo Z; Wu H; Sun L; Su G; Lin Q; Chen H
    Mol Pharm; 2022 Oct; 19(10):3640-3651. PubMed ID: 35917335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Development of PNT6555, a Boronic Acid-Based, Fibroblast Activation Protein-α (FAP)-Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors.
    Poplawski SE; Hallett RM; Dornan MH; Novakowski KE; Pan S; Belanger AP; Nguyen QD; Wu W; Felten AE; Liu Y; Ahn SH; Hergott VS; Jones B; Lai JH; McCann JAB; Bachovchin WW
    J Nucl Med; 2024 Jan; 65(1):100-108. PubMed ID: 38050111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy.
    Yang T; Peng L; Qiu J; He X; Zhang D; Wu R; Liu J; Zhang X; Zha Z
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2331-2341. PubMed ID: 36864362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast Activation Protein Targeting Probe with Gly-Pro Sequence for PET of Glioblastoma.
    Lai C; Cao R; Li R; He C; Wang X; Shi H; Qu C; Qian K; Song S; Chen WH; Cheng Z
    Mol Pharm; 2023 Aug; 20(8):4120-4128. PubMed ID: 37487027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy.
    Pang Y; Zhao L; Fang J; Chen J; Meng L; Sun L; Wu H; Guo Z; Lin Q; Chen H
    J Nucl Med; 2023 Sep; 64(9):1449-1455. PubMed ID: 37321827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The First-in-Human Whole-Body Dynamic Pharmacokinetics Study of Aptamer.
    Ding D; Zhao H; Wei D; Yang Q; Yang C; Wang R; Chen Y; Li L; An S; Xia Q; Huang G; Liu J; Xiao Z; Tan W
    Research (Wash D C); 2023; 6():0126. PubMed ID: 37223462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Furan Donor for NIR-II Molecular Fluorophores with Enhanced Bioimaging Performance.
    Liu C; Li M; Ma H; Hu Z; Wang X; Ma R; Jiang Y; Sun H; Zhu S; Liang Y
    Research (Wash D C); 2023; 6():0039. PubMed ID: 37040521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging Nano-/Biotechnology Drives Oncolytic Virus-Activated and Combined Cancer Immunotherapy.
    Fang C; Xiao G; Wang T; Song L; Peng B; Xu B; Zhang K
    Research (Wash D C); 2023; 6():0108. PubMed ID: 37040283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Characterization of Nanobody-Derived CD47 Theranostic Pairs in Solid Tumors.
    Zhang Y; Zhang D; An S; Liu Q; Liang C; Li J; Liu P; Wu C; Huang G; Wei W; Liu J
    Research (Wash D C); 2023; 6():0077. PubMed ID: 36939440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies.
    Privé BM; Boussihmad MA; Timmermans B; van Gemert WA; Peters SMB; Derks YHW; van Lith SAM; Mehra N; Nagarajah J; Heskamp S; Westdorp H
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1906-1918. PubMed ID: 36813980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-Time-Point PET Analysis of
    Naeimi M; Choyke PL; Dendl K; Mori Y; Staudinger F; Watabe T; Koerber SA; Röhrich M; Debus J; Kratochwil C; Haberkorn U; Giesel FL
    J Nucl Med; 2023 Apr; 64(4):618-622. PubMed ID: 36357183
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.